Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Overcoming Barriers to Therapeutic Access for Hidradenitis Suppurativa
Description
The presentation addresses the challenges faced by patients with Hidradenitis Suppurativa (HS) in accessing therapeutic medications, with a particular focus on prior authorization processes. It begins by acknowledging the frustrations healthcare providers experience when insurance dictates what treatments can be prescribed, impacting patient care. Strategies shared include understanding the specific requirements for different types of insurance, like Medicaid and Medicare, which often require prior treatments or documentation before approving biologics. The speaker emphasizes the importance of thorough documentation of medical history, previous treatments, and disease severity in the clinic notes to facilitate approvals. Additionally, the session discusses resources available to both clinicians and patients, such as patient assistance programs and specialty pharmacies that help manage high-cost medications. The speaker identifies barriers such as high costs, lack of insurance, and insufficient knowledge about biosimilars among healthcare providers as significant hurdles. To improve access, the speaker encourages proactive communication with patients about insurance processes, promoting awareness of available assistance programs, and utilizing standardized prior authorization templates from reliable sources, like the HS Foundation. The final takeaway is a set of best practices to streamline medication approvals, thus enhancing patient access to necessary treatments for HS.
View moreConclusions
- Prior authorizations significantly impact patient access to therapies, particularly for those with high-cost biologics.
- About 46% of patients cite high costs or lack of insurance as major barriers to accessing biologics for treatment.
- A structured approach is essential for navigating the prior authorization process to avoid delays in patient care.
- Patients with Medicaid require trials of systemic antibiotics before approval for biologics, while Medicare typically does not authorize off-label medications.
- Biosimilars' growing presence necessitates an updated understanding among dermatologists to effectively prescribe and manage treatments for patients.
- Specialty pharmacies can enhance patient care by providing additional support, such as medication training and monitoring.
- Documentation of previous treatments and their outcomes is critical in supporting prior authorization requests, reducing chances of denial.
- Patient assistance programs and bridge programs are vital resources for patients who encounter coverage delay or financial hardship.
- Dermatologists express a need for further education on biosimilars, indicating a knowledge gap in their community regarding biosimilar therapeutics.
- JAMA Dermatol. 2023;159(5):510-517. doi:10.1001/jamadermatol.2023.0486
- JOURNAL OF DERMATOLOGICAL TREATMENT. 2022, VOL. 33, NO. 7, 3060-3062.
- J Drugs Dermatol. 2024 Apr 1;23(4):277-280.